NCT04109560

HFNC and Acute Hypercapnic Respiratory Failure

High Flow Nasal Oxygen Therapy in Chronic Obstructive Pulmonary Disease (COPD) Patients With Acute Hypercapnic Respiratory Failure (AHRF)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 40 (actual)
• Sponsor: Argentinian Intensive Care Society · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

High-flow nasal cannula (HFNC) enables delivering humidified gas at high-flow rates controlling the oxygen inspired fraction (FiO2). Its efficacy has been demonstrated in hypoxemic acute respiratory failure. However, little is known about its use in hypercapnic acute respiratory failure (ARF). Therefore, we aimed to evaluate the effect of using HFNC through "Precision Flow" equipment as first line of ventilatory support for COPD patients with hypercapnic acute respiratory failure.

Conditions

• High Flow Oxygen Therapy
• Acute Hypercapnic Respiratory Failure
• COPD Exacerbation

Timeline

• Start date: 2018-08-01
• Primary completion: 2019-09-30
• Completion: 2019-09-30
• First posted: 2019-09-30
• Last updated: 2019-10-23

Locations

1 site across 1 country: Argentina